Company intelligence / Profile preview

Adynxx, Inc.

San Francisco, California, USA

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Adynxx’s lead candidate brivoligide (formerly AYX1) reached Phase 2 clinical trials for the reduction of postoperative pain. Clinical studies suggest a single administration at surgery can reduce pain and opioid use in high-risk patients. Other programs are in preclinical or pending stages targeting chronic and neuropathic pain as well as endometriosis. Some pipeline programs have been discontinued or are pending further development.

Therapeutic areas: Women's HealthNeurology
Modalities: Transcription factor decoy oligonucleotides (short synthetic double-stranded DNA molecules)
Industry: Biotech

Drug pipeline

2 assets

AYX2

Preclinical

1 more asset in the full pipeline.

Partnerships

Collaboration with twoXAR to discover/develop treatments for endometriosis using AI-driven drug discovery technology.

Beyond the preview

Go deeper on Adynxx, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adynxx, Inc..